Correlation of serum homocysteine in patients with chronic heart failure and hypercoagulable state
10.3760/cma.j.issn.1008-1372.2016.09.008
- VernacularTitle:血清同型半胱氨酸与慢性心力衰竭患者血液高凝状态的相关性研究
- Author:
Yuqing ZHANG
;
Guifang ZENG
;
Jie FENG
;
Qian HE
;
Xiang PENG
;
Ying GUO
- Publication Type:Journal Article
- Keywords:
Homocysteine/ME;
Heart failure/ME/PA;
Blood coagulation disorders/ME
- From:
Journal of Chinese Physician
2016;18(9):1313-1315,1319
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the correlation between serum homocysteine (HCY) and chronic heart failure (CHF) hypercoagulable state in patients.Methods A total of 105 cases of patients with CHF was divided into three groups according to the New York Heart Association (NYHA) classification standard functions:heart functional grade Ⅱ group (42cases),cardiac function grade Ⅲ group (35 cases) and,NYHA class Ⅳ group (28cases).At the same time,40 healthy individuals were regard as the control group.HCY,fibrinogen (Fbg),D-dimer (DDI),HCY,N-terminal pro-brain natriuretic peptide (NT-proBNP) were detected by fasting venous blood samples which were collected within 24 hours after admission.Results Compared to the control group,the expression of Fbg,DDI,HCY and NT-proBNP increased,whereas,antithrombin Ⅲ (AT-Ⅲ) was reduced.Fbg,DDI,HCY,NT-proBNP,and AT-Ⅲ were found in all patient cases.Four groups were compared with each other,except for cardiac function Ⅱ group and the normal group had no significant difference between them (P ＞ 0.05),the difference between both other groups was significantly different (P ＜ 0.05),HCY had a positive correlation with Fbg,DDI,and NT-proBNP (r =0.268,0.295,and 0.404,P ＜ 0.05),and negative correlation with AT-Ⅲ (r =-0.240,P ＜ 0.05).Conclusions HCY might be a reliable indicator as a judge of CHF patients with hypercoagulable state,to detect HCY,FBG,DDI,and AT-Ⅲ in CHF patients.It benefits for judging thrombosis risk and determining the severity of the diseases.Anticoagulant therapy might be beneficial to reduce the long-term adverse events.
